The treatment of cognitive impairment associated with parkinson's disease

Brain Pathology

Volumn 20, Issue 3, 2010, Pages 672-678

  Burn, David J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Cholinesterase inhibitor; Cognitive impairment; Dementia; Memantine; Parkinson's disease; Treatment

Indexed keywords

AMANTADINE; ARIPIPRAZOLE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINESTERASE INHIBITOR; CLOZAPINE; DONEPEZIL; DOPAMINE RECEPTOR STIMULATING AGENT; GALANTAMINE; LEVODOPA; MEMANTINE; OLANZAPINE; PERGOLIDE; PIMAVANSERIN; PLACEBO; QUETIAPINE; RISPERIDONE; RIVASTIGMINE; SAFINAMIDE; SELEGILINE; ZIPRASIDONE;

ALZHEIMER DISEASE; BRADYCARDIA; CLINICAL TRIAL; COGNITIVE DEFECT; CONFERENCE PAPER; DEMENTIA; DIAGNOSTIC VALUE; DIFFUSE LEWY BODY DISEASE; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYNDROME; HIP FRACTURE; HUMAN; LOW DRUG DOSE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; NONHUMAN; PARKINSON DISEASE; PSYCHOSIS; TRANSDERMAL PATCH; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT;

COGNITION DISORDERS; DEMENTIA; HUMANS; PARKINSON DISEASE;

EID: 77950845319     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2009.00367.x     Document Type: Conference Paper

References (68)

1. Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sørensen P (2003) Prevalence and characteristics of dementia in Parkinson disease. Arch Neurol 60 : 387 392.
2. Aarsland D, Andersen K, Larsen JP, Lolk A, Nielsen H, Kragh-Sørensen P (2001) Risk of dementia in Parkinson's disease: a community-based prospective study. Neurology 56 : 730 736.
3. Aarsland D, Ballard C, Walker Z, Bostrom F, Alves G, Kossakowski K et al (2009) Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. Lancet Neurol 8 : 613 618.
4. Aarsland D, Brønnick K, Alves G, Tysnes OB, Pedersen KF, Ehrt U, Larsen JP (2009) The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 80 : 928 930.
5. Aarsland D, Brønnick K, Larsen JP, Tysnes OB, Alves G, Group NPS (2009) Cognitive impairment in incident, untreated Parkinson disease: the Norwegian ParkWest study. Neurology 72 : 1121 1126.
6. Aarsland D, Hutchinson M, Larsen JP (2003) Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 18 : 937 941.
7. Aarsland D, Laake K, Larsen JP, Janvin C (2002) Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 72 : 708 712.
8. Allcock LM, Rowan EN, Steen IN, Wesnes K, Kenny RA, Burn DJ (2009) Impaired attention predicts falling in Parkinson's disease. Parkinsonism Relat Disord 15 : 110 115.
9. Ballard C, Ziabreva I, Perry R, Larsen JP, O' Brien J, McKeith I et al (2006) Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology 67 : 1931 1934.
10. Bar-On P, Rockenstein E, Adame A, Ho G, Hashimoto M, Masliah E (2006) Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy. J Neurochem 98 : 1032 1045.
11. Bohnen NI, Kaufer DI, Ivanco LS, Lopresti B, Koeppe RA, Davis JG et al (2003) Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease. Arch Neurol 60 : 1745 1748.
12. Bronnick K, Ehrt U, Emre M, De Deyn PP, Wesnes K, Tekin S, Aarsland D (2006) Attentional deficits affect activities of daily living in dementia-associated with Parkinson's disease. J Neurol Neurosurg Psychiatry 77 : 1136 1142.
13. Burn D, Emre M, McKeith I, De Deyn PP, Aarsland D, Hsu C, Lane R (2006) Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 21 : 1899 1907.
14. Cools R (2006) Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 30 : 1 23.
15. Creeley CE, Wozniak DF, Nardi A, Farber NB, Olney JW (2008) Donepezil markedly potentiates memantine neurotoxicity in the adult rat brain. Neurobiol Aging 29 : 153 167.
16. Dubois B, Burn D, Goetz C, Aarsland D, Brown R, Broe A et al (2007) Diagnostic procedures for Parkinson's disease dementia. Mov Disord 22 : 2314 2324.
17. Dubois B, Tolosa E, Kulisevsky J, Reichman H, Jones R, Burn D et al (2007) Efficacy and safety of donepezil in the treatment of Parkinson's disease patients with dementia. Neurodegenerative Dis 4 (Suppl. 1 90.
18. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP et al (2004) Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 351 : 2509 2518.
19. Emre M, Aarsland D, Brown R, Burn D, Duyckaerts C, Mizuno Y et al (2007) Clinical diagnostic criteria for dementia associated with Parkinson disease. Mov Disord 22 : 1689 1707.
20. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH (2003) Long-term outcome of quetiapine use for psychosis among parkinsonian patients. Mov Disord 18 : 510 514.
21. Foltynie T, Brayne CEG, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson's disease patients in the UK. The CamPaIGN study. Brain 127 : 550 560.
22. Francis PT, Perry EK (2007) Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov Disord 22 (Suppl. 17 S351 S357.
23. Friedman J, Berman RM, Goetz CG, Factor SA, Ondo WG, Wojcieszek J et al (2006) Open-label flexible-dose pilot study to evaluate the safety and tolerabilty of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 21 : 2078 2081.
24. Friedman J, Vanover KE, Taylor EM, Weiner D, Davis RE, van Kammen DP (2006) ACP-103 reduces psychosis without impairing motor function in Parkinson's disease. Mov Disord 21 : 1546.
25. Friedman JH (2006) Atypical antipsychotics in the elderly with Parkinson disease and the "black box" warning. Neurology 67 : 564 566.
26. Gill SS, Anderson GM, Fischer HD, Bell CM, Li P, Normand SL, Rochon PA (2009) Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population-based cohort study. Arch Intern Med 169 : 867 873.
27. Goetz CG, Fan W, Leurgans S (2008) Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. Mov Disord 23 : 1541 1545.
28. Grace J, Amick MM, Friedman JH (2009) A double-blind comparison of galantamine hydrobromide ER and placebo in Parkinson disease. J Neurol Neurosurg Psychiatry 80 : 18 23.
29. Halliday G, Hely M, Reid W, Morris J (2008) The progression of pathology in longitudinally followed patients with Parkinson's disease. Acta Neuropathol 115 : 409 415.
30. Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG (2008) The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 23 : 837 844.
31. Imamura K, Wada-Isoe K, Kowa H, Tanabe Y, Nakashima K (2008) The effect of donepezil on increased regional cerebral blood flow in the posterior cingulate cortex of a patient with Parkinson's disease dementia. Neurocase 14 : 271 275.
32. Inzelberg R, Bonuccelli U, Schechtman E, Miniowich A, Strugatsky R, Ceravolo R et al (2006) Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord 21 : 1375 1379. (Pubitemid 44613288)
33. Kulisevsky J, Garcia-Sanchez C, Berthier ML, Baranoj M, Pascual-Sedano B, Gironell A, Estevez-Gonzalez A (2000) Chronic effects of dopaminergic replacement on cognitive function in Parkinson's disease: a two-year follow-up study of previously untreated patients. Mov Disord 15 : 613 626.
34. Kurlan R, Cummings J, Raman R, Thal L, Group AsDCS (2007) Quetiapine for agitation or psychosis in patients with dementia and parkinsonism. Neurology 68 : 1356 1363.
35. Lee PH, Yong SW, An YS (2008) Changes in cerebral glucose metabolism in patients with Parkinson disease with dementia after cholinesterase inhibitor therapy. J Nucl Med 49 : 2006 2011.
36. Leroi I, Brandt J, Reich SG, Lyketsos CG, Grill S, Thompson R, Marsh L (2004) Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 19 : 1 8.
37. Leroi I, Overshott R, Byrne EJ, Daniel E, Burns A (2009) Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov Disord 24 : 1217 1221.
38. Litvinenko IV, Odinak MM, Mogil'naya VI, Emelin AY (2008) Efficacy and safety of galantamine (reminyl) for dementia in patients with Parkinson's disease (an open controlled trial). Neurosci Behav Physiol 38 : 937 945.
39. Maidment I, Fox C, Boustani M (2006) Cholinesterase inhibitors for Parkinson's disease dementia. Cochrane Database Syst Rev CD004747.
40. Manganelli F, Vitale C, Santangelo G, Pisciotta C, Iodice R, Cozzolino A et al (2009) Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 132 : 2350 2355.
41. Marras C, Kopp A, Qiu F, Lang AE, Sykora K, Shulman KI, Rochon PA (2007) Antipsychotic use in older adults with Parkinson's disease. Mov Disord 15 : 319 323. (Pubitemid 46569683)
42. Marsh L, Biglan K, Gerstenhaber M, Williams JR (2009) Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 24 : 277 282.
43. Martin RC, Okonkwo OC, Hill J, Griffith HR, Triebel K, Bartolucci A et al (2008) Medical decision-making capacity in cognitively impaired Parkinson's disease patients without dementia. Mov Disord 23 : 1867 1874.
44. Mentis MJ, Delalot D, Naqvi H, Gordon MF, Gudesblatt M, Edwards C et al (2006) Anticholinesterase effect on motor kinematic measures and brain activation in Parkinson's disease. Mov Disord 21 : 549 555.
45. Minett TS, Thomas A, Wilkinson LM, Daniel SL, Sanders J, Richardson J et al (2003) What happens when donepezil is suddenly withdrawn? An open label trial in dementia with Lewy bodies and Parkinson's disease with dementia. Int J Geriatr Psychiatry 18 : 988 993.
46. Miyasaki J, Shannon K, Voon V, Ravina B, Kleiner-Fisman G, Anderson K et al (2006) Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 66 : 996 1002. (Pubitemid 44044781)
47. Okello A, Koivunen J, Edison P, Archer HA, Turkheimer FE, Någren K et al (2009) Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study. Neurology 73 : 754 760.
48. Ondo WG, Tintner R, Voung KD, Lai D, Ringholz G (2005) Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 20 : 958 963.
49. Onofrj M, Bonanni L, Thomas A (2008) An expert opinion on safinamide in Parkinson's disease. Expert Opin Investig Drugs 17 : 1115 1125.
50. Onofrj M, Thomas A, Iacono D, Luciano AL, Di Iorio A (2003) The effects of a cholinesterase inhibitor are prominent in patients with fluctuating cognition: a part 3 study of the main mechanism of cholinesterase inhibitors in dementia. Clin Neuropharmacol 26 : 239 251.
51. Parkinson Study G (1999) Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 340 : 757 763.
52. Pilotto A, Franceschi M, D'Onofrio G, Bizzarro A, Mangialasche F, Cascavilla L et al (2009) Effect of a CYP2D6 polymorphism on the effiacy of donepezil in patients with Alzheimer's disease. Neurology 73 : 761 767.
53. Poewe W, Wolters E, Emre M, Onofrj M, Hsu C, Tekin S et al (2006) Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 21 : 456 461.
54. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C (2007) Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 22 : 313 318.
55. Ravina B, Putt M, Siderowf A, Farrar JT, Gillespie M, Crawley A et al (2005) Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 76 : 934 939.
56. Reddy S, Factor SA, Molho ES, Feustel PJ (2002) The effect of quetiapine on psychosis and motor function in parkinsonian patients with and without dementia. Mov Disord 17 : 676 681.
57. Rowland JP, Rigby J, Harper AC, Rowland R (2007) Cardiovascular monitoring with acetylcholinesterase inhibitors: a clinical protocol. Adv Psychiatr Treat 13 : 178 184.
58. Scheltens P (2009) Moving forward with nutrition in Alzheimer's disease. Eur J Neurol 16 (Suppl. 1 19 22.
59. Shimada H, Hirano S, Shinotoh H, Aotsuka A, Sato K, Tanaka N et al (2009) Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology 73 : 273 278.
60. Takahashi RN, Pamplona FA, Prediger RD (2008) Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci 13 : 2614 2632.
61. Tanaka K, Quadros ACJ, Santos RF, Stella F, Gobbi LT, Gobbi S (2009) Benefits of physical exercise on executive functions in older people with Parkinson's disease. Brain Cogn 69 : 435 441.
62. The French Clozapine Parkinson Study Group (1999) Clozapine in drug-induced psychosis in Parkinson's disease. Lancet 353 : 2041 2042.
63. The National Collaborating Centre for Chronic Conditions (2006) Parkinson's Disease: National Clinical Guideline for Diagnosis and Management in Primary and Secondary Care. Royal College of Physicians
64. Thomsen TR, Panisset M, Suchowersky O, Goodridge A, Mendis T, Lang AE (2008) Impact of standard of care for psychosis in Parkinson disease. J Neurol Neurosurg Psychiatry 79 : 1413 1415.
65. Tiraboschi P, Hansen LA, Alford M, Sabbagh MN, Schoos B, Masliah E et al (2000) Cholinergic dysfunction in diseases with Lewy bodies. Neurology 54 : 407 411.
66. Wesnes KA, McKeith I, Edgar C, Emre M, Lane R (2005) Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology 65 : 1654 1656. (Pubitemid 41689487)
67. Williams-Gray CH, Foltynie T, Brayne CEG, Robbins TW, Barker RA (2007) Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 130 : 1787 1798.
68. Youdim MB, Amit T, Bar-Am O, Weinreb O, Yogev-Falach M (2006) Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Neurotox Res 10 : 181 192.